Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
The high health care burden faced by individuals with hemophilia underscores the urgent need for innovative treatments and improved diversity in clinical trials.
Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.
The 2024 American Urological Association (AUA) annual meeting in San Antonio strongly emphasized diversity, equity, and inclusion, as well as innovations in robotic surgery and research methodologies.
The 2024 American Academy of Dermatology conference was held in San Diego, California March 8 to 11.
Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.
Our top content from the 100th annual American Heart Association (AHA) Scientific Sessions included exclusive expert insights and highlighted promising treatments.
Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, a factor XI (FXI) inhibitor, to reduce bleeding risk in atrial fibrillation treatment.
Among the most-read coverage for the annual meeting were presentations on the potential and costs of cell and gene therapies, the latest trends in the industry, and pharmacogenomic testing in mental health.
The top 5 most-viewed content from CHEST 2024 included expert interviews and coverage on multiple areas of chest medicine.
A pair of studies from The American Society of Hematology (ASH) Annual Meeting & Exposition provides insights into the prognostic utility of geriatric assessment tools and their role in tailoring therapy to improve patient outcomes.
Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.
Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of covalent Bruton’s tyrosine kinase inhibitors (cBTKis) in patients with chronic lymphocytic leukemia (CLL).
Health care conferences this year showcased advancements in treatments for chronic obstructive pulmonary disease and sleep apnea, discussions around health policy and economic research, and more.
The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.
Experts discussed the great advances and innovations they’ve seen this year in acute myeloid leukemia (AML) and multiple myeloma.
Haydar Frangoul, MD, MS, medical director, Pediatric Hematology/Oncology for Sarah Cannon Research Institute at TriStar Centennial Children’s Hospital, Nashville, presented the data on the long-term efficacy and safety for participants with sickle cell disease (SCD) who received exa-cel.
The top 5 most-viewed content from this year's American Thoracic Society (ATS) 2024 International Conference featured an interview with Monica Kraft, MD, ASTF, and coverage of multiple respiratory and pulmonary medicine areas.
The American Society of Hematology is launching a health equity effort, "Treating Fairly," which was discussed at the quality symposium at the 66th Annual Meeting & Exposition.
Results of a small study presented at the 66th American Society of Hematology Annual Meeting & Exposition suggest combining the bispecific elranatamab with the proteasome inhibitor carfilzomib can bring responses even in patients with stage III disease.
Experts at the Council for Affordable Quality Healthcare (CAQH) Connect 2024 emphasized the transformative potential of artificial intelligence (AI) and predictive analytics in addressing health care challenges, advancing equity, and reducing clinician burden.
A pair of studies presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition highlight continuing gaps in hemophilia care despite the availability of prophylactic therapies.
Top coverage from the 2024 European Society of Cardiology (ESC) Congress focused on screening, treatment, and equity in cardiovascular care.
Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).
Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, with key research presented on immune thrombocytopenia, hemophilia, and multiple myeloma.
Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction in disease progression or death compared with standard-of-care endocrine therapy.
Yi Lin, MD, PhD, hematologist and oncologist, Mayo Clinic, discusses the efficacy of ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor T-cell therapy vs standard treatments for patients with multiple myeloma.
Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among Black patients compared with clinical trials.
By reducing cytokine release syndrome and neurotoxicity, prophylactic tocilizumab could facilitate safe outpatient administration of bispecifics to treat multiple myeloma (MM), explained Robert Rifkin, MD.
Two posters presented at the 2024 American Society of Hematology meeting bolster evidence supporting the long-term clinical benefits of ruxolitinib for polycythemia vera and chronic graft-vs-host disease.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
